[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363655-105":59,"doc-detail-363655-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","peptide-mediated-immunomodulation-of-tumor-microenvironment-in-triple-negative-breast-cancer-a-comprehensive-review","Peptide-mediated immunomodulation of tumor microenvironment in triple-negative breast cancer: A comprehensive review","","Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype defined by the absence of estrogen receptor, progesterone receptor, and HER2 expression, which limits molecularly targeted therapies. Despite limited standard options and high recurrence, metastasis, and resistance rates, TNBC often contains tumor-infiltrating lymphocytes and elevated PD-L1, creating a rationale for immunotherapy. This comprehensive review focuses on designing immunomodulatory peptides that reshape the tumor microenvironment by modulating innate and adaptive immune cells, including macrophages, neutrophils, dendritic cells, natural killer cells, and T cells. It also discusses peptide-based immune checkpoint inhibitors and emerging strategies using peptides to induce immunogenic cell death that activates dendritic cells and T cells, highlighting therapeutic promise for durable TNBC treatment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/peptide-mediated-immunomodulation-of-tumor-microenvironment-in-triple-negative-breast-cancer-a-comprehensive-review/363655/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/peptide-mediated-immunomodulation-of-tumor-microenvironment-in-triple-negative-breast-cancer-a-comprehensive-review/363655.png","ImageObject",300,407,{"name":92,"@type":93},"Kurz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is triple-negative breast cancer challenging to treat with conventional targeted therapies?","Question",{"text":112,"@type":113},"TNBC lacks estrogen receptor, progesterone receptor, and HER2 expression, which removes established molecular targets and contributes to limited treatment options and higher resistance to conventional therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do immunomodulatory peptides act in the tumor microenvironment of TNBC?",{"text":117,"@type":113},"The review explains that peptides modulate immune cells within the tumor microenvironment, including innate cells (macrophages, neutrophils, dendritic cells, NK cells) and adaptive T cells, to enhance antitumor immunity and reshape TME crosstalk.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the role of peptide-induced immunogenic cell death in this review?",{"text":121,"@type":113},"It describes peptides that trigger immunogenic cell death, promoting the release of damage-associated molecular patterns that further activate dendritic cells and T cells, strengthening antitumor immune responses.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363655,1790460101,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","The Journal of Pharmacology and Experimental Therapeutics 393 (2026) 104324  \nThe Journal of Pharmacology and Experimental Therapeutics  \njournal [homepage:](homepage: www . j pet. as petjournals . o rg)[ www . j pet. as petjournals . o rg](homepage: www . j pet. as petjournals . o rg)  \n| \u003Cbr>MINIREVIEW\u003Cbr>Peptide-mediated immunomodulation of tumor microenvironment in triple-negative breast cancer: A comprehensive review |  |  |  | |\n| --- | --- | --- | --- | --- |\n| Adnan Murad Bhayo 1, Paola Marcato 2, 3, 4, 5, Marya Ahmed 1, 4, 6, *\u003Cbr>1 Department of Chemistry, University of Prince Edward Island, Charlottetown, Prince Edward Island, Canada\u003Cbr>2 Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada\u003Cbr>3 Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada\u003Cbr>4 Beatrice Hunter Cancer Research Institute, Dalhousie University, Halifax, Nova Scotia, Canada\u003Cbr>5 Nova Scotia Health Authority, Halifax, Nova Scotia, Canada\u003Cbr>6 Donadeo Innovation Centre for Engineering, University of Alberta, Edmonton, Alberta, Canada |  |  | |  |\n| a r t i c l e i n f o |  | a b s t r a c t |  |  |\n| Article history:\u003Cbr>Received 2 December 2025 Accepted 24 March 2026 Available online 31 March 2026 |  | Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. The absence of molecular targets in TNBC limits treatment options and contributes to increased rates of recurrence, metastasis, and resistance to conventional therapies. TNBC, however, is rich in tumor-infiltrating lymphocytes; hence, elevated programmed death-ligand 1 expression makes these tumors amenable to immunotherapy. A variety of antibodies and immunomodulatory drugs are being explored for TNBC treatment, this review specifically focuses on design of immunomodulatory peptides for TNBC treatment. This review comprehensively discusses the peptide-based approaches for immunomodulating tumor microenvironment (TME) of TNBC and to enhance antitumor immune response. The peptide-mediated modulation of innate immune cells including tumor-associated macrophages, neutrophils, dendritic cells, and natural killer cells, as well as T cells of the adaptive immune system is explored in detail. The applications of peptides as immune checkpoint inhibitors and highlights of emerging strategies that employ peptides to induce immunogenic cell death to stimulate antitumor immunity are discussed. Immunogenic cell death inducing peptides promote the release of immunogenic signals such as damage-associated molecular patterns from dying cancer cells, which further activate dendritic cells, T cells, and neutrophils, thereby reshaping the TME to support robust antitumor immunity. These strategies underscore the transformative potential of peptide therapeuticsto harness the immune system and reshape TME, offering a promising avenue for more effective and durable TNBC treatment.\u003Cbr>Significance Statement: With growing interest in peptides as tumor microenvironment modulator, this review provides an in-depth analysis of interactions and crosstalk between immune and tumor cells and explores therapeutic potential of peptides in modulating immune cell signaling pathways, with ultimate impact as anticancer agents for triple-negative breast cancer.\u003Cbr>© 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics. This is an open access article under the CC BY-NC-ND license ([http://](http://)[ ](http://)[creativecommons.org/licenses/by-nc-nd/4.0/](creativecommons.org/licenses/by-nc-nd/4.0/)). |  |  |\n| Key words:\u003Cbr>Triple-negative breast cancer Tumor microenvironment Immunomodulatory peptide Immunotherapy\u003Cbr>Breast cancer treatment |  |  |  |  |\n\n* Address correspondence to: Marya Ahmed, Donadeo Innovation Centre for Engineering, Univers","cbCaijnwFd0GFJd2","https://ap.wps.com/l/cbCaijnwFd0GFJd2","pdf",16558614,22,"English","# Introduction\n# Peptide-mediated immunomodulation of the tumor microenvironment\n## Innate immune cells in TNBC\n## Adaptive immune responses in TNBC\n## Peptides as immune checkpoint inhibitors\n## Peptides inducing immunogenic cell death\n# Significance and therapeutic outlook","[{\"question\":\"Why is triple-negative breast cancer challenging to treat with conventional targeted therapies?\",\"answer\":\"TNBC lacks estrogen receptor, progesterone receptor, and HER2 expression, which removes established molecular targets and contributes to limited treatment options and higher resistance to conventional therapies.\"},{\"question\":\"How do immunomodulatory peptides act in the tumor microenvironment of TNBC?\",\"answer\":\"The review explains that peptides modulate immune cells within the tumor microenvironment, including innate cells (macrophages, neutrophils, dendritic cells, NK cells) and adaptive T cells, to enhance antitumor immunity and reshape TME crosstalk.\"},{\"question\":\"What is the role of peptide-induced immunogenic cell death in this review?\",\"answer\":\"It describes peptides that trigger immunogenic cell death, promoting the release of damage-associated molecular patterns that further activate dendritic cells and T cells, strengthening antitumor immune responses.\"}]","Peptide-mediated immunomodulation of tumor microenvironment in triple-negative breast cancer: A comprehensive review | PDF",1790152484,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f54da69f54b6736b9e22296788f58ef.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61ab6a6f6dcf0a82daae6b90de0a6d17.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ccb6186d160c6dfcbcd6dcc9dc45484a.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/731cbb6faae25732c960f97f46314e9e.webp",980,731]